Cargando…
Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
PURPOSE: This study aimed to report the early toxicity results of a prospective clinical trial of prostate stereotactic body radiation therapy (SBRT) to the entire prostate with a simultaneous integrated boost (SIB) to magnetic resonance imaging (MRI)-defined focal lesions. METHODS AND MATERIALS: El...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349624/ https://www.ncbi.nlm.nih.gov/pubmed/30706015 http://dx.doi.org/10.1016/j.adro.2018.09.007 |
_version_ | 1783390289444995072 |
---|---|
author | McDonald, Andrew M. Dobelbower, Michael C. Yang, Eddy S. Clark, Grant M. Jacob, Rojymon Kim, Robert Y. Cardan, Rex A. Popple, Richard Nix, Jeffrey W. Rais-Bahrami, Soroush Fiveash, John B. |
author_facet | McDonald, Andrew M. Dobelbower, Michael C. Yang, Eddy S. Clark, Grant M. Jacob, Rojymon Kim, Robert Y. Cardan, Rex A. Popple, Richard Nix, Jeffrey W. Rais-Bahrami, Soroush Fiveash, John B. |
author_sort | McDonald, Andrew M. |
collection | PubMed |
description | PURPOSE: This study aimed to report the early toxicity results of a prospective clinical trial of prostate stereotactic body radiation therapy (SBRT) to the entire prostate with a simultaneous integrated boost (SIB) to magnetic resonance imaging (MRI)-defined focal lesions. METHODS AND MATERIALS: Eligible patients included men with biopsy-proven prostate stage T1c to T2c adenocarcinoma, a Gleason score ≤7, and prostate-specific antigen values of ≤20 ng/mL, who had at least 1 focal lesion visible on MRI and a total prostate volume no greater than 120 cm(3). SBRT consisted of a dose of 36.25 Gy to the entire prostate with an SIB of 40 Gy to the MRI-defined lesions, delivered in 5 fractions. The primary purpose of the study was to confirm the feasibility of treatment planning/delivery and to estimate the rate of urinary retention requiring placement of a Foley catheter within 90 days of treatment. This study was to be considered successful if urinary retention occurred in no more than 15% of cases, with a planned enrollment of at least 25 patients. RESULTS: A total of 26 men were enrolled, and all underwent SBRT as planned. Twenty patients (77%) had intermediate-risk features, and the remainder were low risk. A treatment plan that met the protocol-defined goals for all cases was developed. Two patients (7.7%) developed acute urinary symptoms that required the temporary placement of a Foley catheter. No grade 3+ toxicity events were observed. CONCLUSIONS: Planning and delivery of prostate SBRT with a whole prostate dose of 36.25 Gy and a focal 40 Gy SIB is feasible. Early follow-up suggests that this treatment is not associated with undue morbidity. |
format | Online Article Text |
id | pubmed-6349624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63496242019-01-31 Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial McDonald, Andrew M. Dobelbower, Michael C. Yang, Eddy S. Clark, Grant M. Jacob, Rojymon Kim, Robert Y. Cardan, Rex A. Popple, Richard Nix, Jeffrey W. Rais-Bahrami, Soroush Fiveash, John B. Adv Radiat Oncol Genitourinary Cancer PURPOSE: This study aimed to report the early toxicity results of a prospective clinical trial of prostate stereotactic body radiation therapy (SBRT) to the entire prostate with a simultaneous integrated boost (SIB) to magnetic resonance imaging (MRI)-defined focal lesions. METHODS AND MATERIALS: Eligible patients included men with biopsy-proven prostate stage T1c to T2c adenocarcinoma, a Gleason score ≤7, and prostate-specific antigen values of ≤20 ng/mL, who had at least 1 focal lesion visible on MRI and a total prostate volume no greater than 120 cm(3). SBRT consisted of a dose of 36.25 Gy to the entire prostate with an SIB of 40 Gy to the MRI-defined lesions, delivered in 5 fractions. The primary purpose of the study was to confirm the feasibility of treatment planning/delivery and to estimate the rate of urinary retention requiring placement of a Foley catheter within 90 days of treatment. This study was to be considered successful if urinary retention occurred in no more than 15% of cases, with a planned enrollment of at least 25 patients. RESULTS: A total of 26 men were enrolled, and all underwent SBRT as planned. Twenty patients (77%) had intermediate-risk features, and the remainder were low risk. A treatment plan that met the protocol-defined goals for all cases was developed. Two patients (7.7%) developed acute urinary symptoms that required the temporary placement of a Foley catheter. No grade 3+ toxicity events were observed. CONCLUSIONS: Planning and delivery of prostate SBRT with a whole prostate dose of 36.25 Gy and a focal 40 Gy SIB is feasible. Early follow-up suggests that this treatment is not associated with undue morbidity. Elsevier 2018-09-19 /pmc/articles/PMC6349624/ /pubmed/30706015 http://dx.doi.org/10.1016/j.adro.2018.09.007 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Genitourinary Cancer McDonald, Andrew M. Dobelbower, Michael C. Yang, Eddy S. Clark, Grant M. Jacob, Rojymon Kim, Robert Y. Cardan, Rex A. Popple, Richard Nix, Jeffrey W. Rais-Bahrami, Soroush Fiveash, John B. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title_full | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title_fullStr | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title_full_unstemmed | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title_short | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial |
title_sort | prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial |
topic | Genitourinary Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349624/ https://www.ncbi.nlm.nih.gov/pubmed/30706015 http://dx.doi.org/10.1016/j.adro.2018.09.007 |
work_keys_str_mv | AT mcdonaldandrewm prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT dobelbowermichaelc prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT yangeddys prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT clarkgrantm prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT jacobrojymon prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT kimroberty prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT cardanrexa prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT popplerichard prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT nixjeffreyw prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT raisbahramisoroush prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial AT fiveashjohnb prostatestereotacticbodyradiationtherapywithafocalsimultaneousintegratedboostacutetoxicityanddosimetryresultsfromaprospectivetrial |